Company research
VBI Vaccines Inc/BC
CIK 764195Updated Sep 26, 2026
Name history
SciVac Therapeutics Inc. · through Jun 13, 2016LEVON RESOURCES LTD. · through Jul 17, 2015LEVON RESOURCES LTD · through Sep 7, 2010
Filing activity
Latest filing
50 filings on record · EFFECT, 8-K, POS AM, S-8 POS, 25-NSE, 424B5.
Recent filings
EFFECT filing
Completion of Acquisition or Disposition of Assets · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 2.01, 3.03, 5.01, 5.02, 8.01, 9.01
POS AM filing
S-8 POS filing
S-8 POS filing
Show 5 more recent filings
Financials
FY 2023 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 86,951,000Source | 155,086,000Source | 210,276,000Source | 209,372,000Source |
| Property, Plant and Equipment, NetUSD | 9,665,000Source | 12,253,000Source | 11,037,000Source | 10,721,000Source |
| GoodwillUSD | 1,130,000Source | 2,127,000Source | 2,261,000Source | 2,261,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 36,499,000Source | 58,345,000Source | 62,091,000Source | 62,156,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | 93,825,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 94,000Source | 8,000Source | 77,000Source |
| Inventory, NetUSD | 8,499,000Source | 6,599,000Source | 2,576,000Source | 2,152,000Source |
| Assets, CurrentUSD | 36,231,000Source | 77,690,000Source | 130,284,000Source | 132,041,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,248,000Source | 3,316,000Source | 3,344,000Source | 1,554,000Source |
| Other Assets, NoncurrentUSD | 1,178,000Source | 1,355,000Source | 1,259,000Source | 639,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 454,214,000Source | 442,312,000Source | 442,235,000Source | 403,528,000Source |
| Additional Paid in CapitalUSD | — | — | 81,583,000Source | 75,530,000Source |
| Retained Earnings (Accumulated Deficit)USD | -582,445,000Source | -489,609,000Source | -378,371,000Source | -308,618,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 28,327,000Source | 21,440,000Source | -1,565,000Source | 1,265,000Source |
| Stockholders' Equity Attributable to ParentUSD | 7,527,000Source | 64,163,000Source | 143,882,000Source | 171,705,000Source |
| Additional Paid in Capital, Common StockUSD | 107,431,000Source | 90,020,000Source | — | — |
| Liabilities and EquityUSD | 86,951,000Source | 155,086,000Source | 210,276,000Source | 209,372,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 75,736,000Source | 36,942,000Source | 32,586,000Source | 17,348,000Source |
| Operating Lease, Liability, CurrentUSD | 976,000Source | 972,000Source | 839,000Source | 944,000Source |
| Accounts Payable, CurrentUSD | 6,431,000Source | 12,973,000Source | 4,280,000Source | 3,734,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,295,000Source | 2,365,000Source | 2,516,000Source | 619,000Source |
| Additional Financial Items | ||||
| Long-term DebtUSD | 50,769,000Source | 48,888,000Source | 28,441,000Source | 16,329,000Source |
| Long-term Debt, Current MaturitiesUSD | 50,769,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 48,888,000Source | 28,441,000Source | 16,329,000Source |
| Short-term InvestmentsUSD | — | — | — | 25,276,000Source |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,990,000Source | 2,061,000Source | 1,835,000Source | 1,652,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,661,000Source | 9,698,000Source | 9,628,000Source | 5,287,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -99,000Source | 87,000Source | -69,000Source | -130,000Source |
| Increase (Decrease) in InventoriesUSD | 3,718,000Source | 5,690,000Source | 513,000Source | 1,946,000Source |
| Increase (Decrease) in Accounts PayableUSD | -6,652,000Source | 8,893,000Source | 356,000Source | 2,059,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -60,883,000Source | -73,695,000Source | -39,908,000Source | -47,050,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -867,000Source | -4,344,000Source | 23,156,000Source | -26,000,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 867,000Source | 4,344,000Source | 1,995,000Source | 1,000,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 22,698,000Source | 19,449,000Source | 44,293,000Source | 122,392,000Source |
| Repayments of Long-term DebtUSD | — | — | — | 15,300,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -38,944,000Source | -59,065,000Source | 27,869,000Source | 49,612,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,130,000Source | 3,231,000Source | 2,039,000Source | 1,608,000Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance Costs and DiscountsUSD | 1,881,000Source | 1,707,000Source | 1,838,000Source | 1,569,000Source |
| Amortization of Intangible AssetsUSD | — | 52,000Source | 67Source | 64,000Source |
| DepreciationUSD | 1,990,000Source | 2,009,000Source | 1,768Source | 1,588,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -6,524,000Source | -27,476,000Source | 3,011,000Source | 95,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -6,609,000Source | -27,445,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | -172,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 38,335,000Source | 20,651,000Source |
| GoodwillUSD | 1,130,000Source | 2,127,000Source | 2,261,000Source | 2,261,000Source |
| Goodwill, Impairment LossUSD | 1,000,000Source | — | — | — |
| Investment Income, InterestUSD | 1,663,000Source | 1,387,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -92,836,000Source | -113,303,000Source | -69,753,000Source | -46,230,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -93,841,000Source | — | — | — |
| Operating Costs and ExpensesUSD | 12,507,000Source | 11,276,000Source | 10,770,000Source | — |
| Operating ExpensesUSD | 88,593,000Source | 82,902,000Source | 68,663,000Source | 44,678,000Source |
| Proceeds from Issuance of Common StockUSD | 24,273,000Source | — | 33,293,000Source | 122,185,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 12,000Source | 4,000Source | 1,000Source |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Total RevenueUSD | 8,682,000Source | 1,082,000Source | 631,000Source | 1,061,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 42,143,000Source | 56,120,000Source | — | — |
| Operating Income (Loss)USD | -79,911,000Source | -81,820,000Source | -68,032,000Source | -43,617,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -92,836,000Source | -113,303,000Source | -69,753,000Source | -46,230,000Source |
| Net Income (Loss) Attributable to ParentUSD | -92,836,000Source | -113,303,000Source | -69,753,000Source | -46,230,000Source |
| Earnings Per Share, BasicUSD per share | -6.03Source | -0.44Source | — | — |
| Earnings Per Share, DilutedUSD per share | -6.03Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 15,572,494Source | 258,257,296Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 15,572,494Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 52,000Source | 67Source | 64,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -6,524,000Source | -27,476,000Source | 3,011,000Source | 95,000Source |
| General and Administrative ExpenseUSD | — | — | 38,335,000Source | 20,651,000Source |
| Goodwill, Impairment LossUSD | 1,000,000Source | — | — | — |
| Interest ExpenseUSD | 6,401,000Source | 4,007,000Source | 4,732,000Source | 2,708,000Source |
| Interest Expense, DebtUSD | 6,183,000Source | 3,515,000Source | 2,105,000Source | 1,752,000Source |
| Investment Income, InterestUSD | 1,663,000Source | 1,387,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -93,841,000Source | — | — | — |
| Operating Costs and ExpensesUSD | 12,507,000Source | 11,276,000Source | 10,770,000Source | — |
| Operating ExpensesUSD | 88,593,000Source | 82,902,000Source | 68,663,000Source | 44,678,000Source |
| Research and Development ExpenseUSD | 9,343,000Source | 15,506,000Source | 19,558,000Source | 14,859,000Source |
Filing attachments
ex99-1.htm · 8-K · 2025-01-03
EX-99.1 2 ex99-1.htm Exhibit 99.1 VBI Vaccines Announces Completion of Sales Process to K2 CAMBRIDGE, Mass. - January 3, 2025 - VBI Vaccines Inc. (“ VBI ” or the “ Company ”) today announced, that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act (Canada) (the “ CCAA ”) and its previously announced sale and investment solicitation process, the Company completed the transactions (together, the “ Transaction ”) contemplated by that certain …
Read attachment ↗ex99-2.htm · 8-K · 2025-01-03
EX-99.2 3 ex99-2.htm Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Name and Address of Company ────────────────────────── VBI Vaccines Inc. (the “ Company ”) 160 Second Street, 3 rd Floor Cambridge, Massachusetts, United States 02142 Dates of Material Change ────────────────────── January 3, 2025. News Releases ──────────── A press release was disseminated on January 3, 2025, through newswire and the Company’s website. 4 Summary of Material Cha…
Read attachment ↗